Kyriakos Mikellis, head of Pfizer in Cyprus and Malta, has been re-elected President of the Cyprus Association of Pharmaceutical Research and Development Companies (KEFEA), for a period of two years.
According to an announcement by the KEFEA, Mr. Mikellis, after his re-election, thanked the Board of Directors of the Association for renewing their confidence in him, noting that the KEFEA's priorities for the coming period are to ensure patients' access to the most appropriate treatment for each case.
He added that this can only be achieved through the full implementation of the provisions of the legislation and the memorandum of understanding that Pfizer signed with the Ministry of Health and the Health Insurance Agency.
As Mr. Mikellis, two and a half years after the implementation of the GESY, there are still significant outstanding issues resulting in problems in patient access to treatments, especially innovative ones, while the further delay in the implementation of the provisions creates conditions of concern and doubt among providers for the next day.
He noted that it is the KEFEA's belief that all medicines should be available within the GHS in both primary and secondary pharmaceutical care.
It is also equally important, however, that their prescription and dispensing be based on guidelines, which should be based on international data and practices, with local scientific societies actively involved in their formulation, he continued.
In conclusion, he assured that the KEFEA remains open to dialogue with all relevant stakeholders, always with a view to creating an environment that will enable the provision of high quality health services, including medication, to patients."
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source
